Trial Search Results
A 5-year Longitudinal Observational Study of the Natural History and Management of Patients With HCC
TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual clinical practice. TARGET-HCC will create a research registry of participants with HCC within academic and community real-world practices in order to assess the safety and effectiveness of the entire spectrum of current and future therapies across diverse populations.
Stanford is currently accepting patients for this trial.
Target PharmaSolutions, Inc.
1. Male or female patients, age ≥18 years
2. Patients with a histological/cytological or radiological diagnosis of HCC (mixed HCC
cholangiocarcinoma may be included; patients who are candidates for surgical and
non-surgical treatment, as well as those being followed without specific HCC therapy
may be included)
1. Inability to provide written informed consent
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study